Article
A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
PLoS medicine - 1 Jan 2007
Nijhuis Monique, van Maarseveen Noortje M, Lastere Stephane, Schipper Pauline, Coakley Eoin, Glass Bärbel, Rovenska Mirka, de Jong Dorien, Chappey Colombe, Goedegebuure Irma W, Heilek-Snyder Gabrielle, Dulude Dominic, Cammack Nick, Brakier-Gingras Lea, Konvalinka Jan, Parkin Neil, Kräusslich Hans-Georg, Brun-Vezinet Francoise, Boucher Charles A B
Abstract excerpt
BACKGROUND: HIV protease inhibitor (PI) therapy results in the rapid selection of drug resistant viral variants harbouring one or two substitutions in the viral protease. To combat PI resistance development, two approaches have been developed. The first is to increase the level of PI in the plasma of the patient, and the second is to develop novel PI with high potency against the known PI-resistant HIV protease...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.